2022
Does Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy?
Horattas I, Fenton A, Gabra J, Mendiola A, Li F, Namm J, Solomon N, Gass J, Lum S, Murray M, Howard-McNatt M, Dupont E, Levine E, Brown E, Ollila D, Chiba A, Chagpar AB. Does Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy? The American Surgeon 2022, 88: 1607-1612. PMID: 34982015, DOI: 10.1177/00031348211069783.Peer-Reviewed Original ResearchConceptsCavity shave marginsMargin statusPartial mastectomyMolecular subtypesBreast cancer stage IOverall positive margin rateStandard partial mastectomyBreast-conserving therapyCancer stage IInvasive breast cancerImpact of subtypePositive margin rateBreast cancer subtypesLymphovascular invasionSurgical therapySystemic therapyRandomized trialsSurgical marginsShave marginsInvasive carcinomaMargin rateBreast cancerHispanic ethnicityStage IPatients
2020
Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsEnd of lifeUse of chemotherapySystemic cancer therapySystemic therapyCheckpoint inhibitorsColon cancerElectronic health record-derived databaseUse of ICIsFDA approvalCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerMSS colon cancerPearson's chi-square testDrug Administration approvalPatient-level dataCancer therapyDays of lifeChi-square testAggressive therapyBiologic therapyPatient characteristicsTreatment patternsThe adoption of immune checkpoint inhibitors and patterns of care at the end of life.
Riaz F, Gan G, Li F, Davidoff A, Adelson K, Presley C, Adamson B, Shaw P, Parikh R, Mamtani R, Gross C. The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Journal Of Clinical Oncology 2020, 38: 12027-12027. DOI: 10.1200/jco.2020.38.15_suppl.12027.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint inhibitorsUse of chemotherapyMSS colon cancerEnd of lifeSystemic therapySystemic cancer therapyColon cancerFDA approvalCheckpoint inhibitorsBiologic therapyPatient characteristicsUse of ICIsCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerPearson's chi-square testPatient-level dataCancer therapyDays of lifeDe-identified databaseSignificant increaseChi-square testAggressive therapy